Ceftriaxone and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Ceftriaxone (ceftriaxone sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Acetaminophen, and have Asthma.

The phase IV clinical study analyzes which people have Mobility decreased when taking Ceftriaxone. It is created by eHealthMe based on reports of 40,872 people who have side effects when taking Ceftriaxone from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,775 drugs and 1,636 conditions by eHealthMe. Check the latest studies of Mobility decreased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

40,872 people reported to have side effects when taking Ceftriaxone.
Among them, 58 people (0.14%) have Mobility decreased.

Could Ceftriaxone cause Mobility decreased?

Among these 58 people:

How long have people been on Ceftriaxone when they have Mobility decreased? *

What is the gender of people who have Mobility decreased when taking Ceftriaxone? *

female: 52.63 %
male: 47.37 %

What is the age of people who have Mobility decreased when taking Ceftriaxone? *

What are other drugs people take besides Ceftriaxone? *

What are other side effects people have besides Mobility decreased? *

Fever: 24 people, 41.38%
Fatigue (feeling of tiredness): 20 people, 34.48%
Stress And Anxiety: 17 people, 29.31%
Pain: 16 people, 27.59%
Infection: 14 people, 24.14%
Weakness: 14 people, 24.14%
Dyspnea (difficult or laboured breathing): 13 people, 22.41%
Diarrhea: 13 people, 22.41%
Back Pain: 13 people, 22.41%
Pneumonia: 13 people, 22.41%

What are the existing conditions these people have? *

Asthma: 9 people, 15.52%
Dehydration (dryness resulting from the removal of water): 6 people, 10.34%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 10.34%
Urinary Tract Infection: 6 people, 10.34%
Immunodeficiency Common Variable: 6 people, 10.34%
High Blood Cholesterol: 5 people, 8.62%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 6.90%
Pain: 4 people, 6.90%
Oedema Peripheral (superficial swelling): 3 people, 5.17%
Birth Control: 3 people, 5.17%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftriaxone:

Ceftriaxone (40,991 reports)

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,775 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,636 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Ceftriaxone) and Ceftriaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.